First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea

Published:2022-02-26 Issue:3 Volume:42 Page:1615-1622
ISSN:0250-7005
Container-title:Anticancer Research
language:en
Short-container-title:Anticancer Res

Author:

KIM MI-HYUN,CHOI CHANG MIN,LEE SUNG YONG,PARK CHEOL KYU,CHANG YOON SOO,LEE KYE YOUNG,KIM SEUNG JOON,YANG SEI HOON,RYU JEONG SEON,LEE JEONG EUN,LEE SHIN YUP,PARK CHAN KWON,LEE SANG HOON,JANG SEUNG HUN,YOON SEONG HOON,JANG TAE WON

Publisher

Anticancer Research USA Inc.

Subject

Cancer Research,Oncology,General Medicine

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Osimertinib in uncommon EGFR exon 21 L861R and EGFR exon 18 deletion-insertion mutant non-small cell lung cancer—case report;Translational Lung Cancer Research;2024-02

2. Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam;Therapeutic Advances in Medical Oncology;2024-01

3. Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data;Translational Lung Cancer Research;2023-11

4. Epidermal growth factor receptor compound and concomitant mutations: advances in precision treatment strategies;Chinese Medical Journal;2023-06-27

5. Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review;Current Oncology;2023-05-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP